Lawsuit Alert: Investors who lost money with shares of Skye Bioscience, Inc. (NASDAQ: SKYE) should contact the Shareholders Foundation

An investor, who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE), filed a lawsuit over alleged violations of Federal Securities Laws by Skye Bioscience, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE) have certain options and for certain investors are short and strict deadlines running. Deadline: January 16, 2026. NASDAQ: SKYE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Diego, CA based Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.

In August 2024, Skye Bioscience, Inc initiated its "CBeyond" clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess nimacimab as a treatment for obesity and overweight. The CBeyond trial's primary endpoint was to demonstrate an 8% difference in mean weight loss using nimacimab versus placebo at twenty-six weeks, with a thirteen-week follow-up.
At all relevant times while the Phase 2a Beyond trial was ongoing, Skye Bioscience, Inc touted nimacimab's purported "differentiated" mechanism of action and efficacy results as purportedly demonstrated in other various studies. Critically, Skye Bioscience, Inc cited to nimacimab's purportedly potent efficacy as observed in these various studies to suggest that the results of the Phase 2a CBeyond trial were likely to be favorable, while consistently touting nimacimab's overall clinical, regulatory, and commercial prospects.

Then on October 6, 2025, Skye Bioscience, Inc issued a press release "announcing the topline data from its 26-week Phase 2a CBeyondTM proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody." The press release disclosed that the "the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo" and that "preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy."

Skye Bioscience, Inc. (NASDAQ: SKYE) declined from $5.96 per share on November 08, 2204, to as low as $1.10 per share on December 02, 2025.

According to the complaint the plaintiff alleges on behalf of purchasers of Skye Bioscience, Inc. (NASDAQ: SKYE) common shares between November 4, 2024 and October 3, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 4, 2024 and October 3, 2025, the Defendants made false and/or misleading statements and/or failed to disclose that nimacimab was less effective than Defendants had led investors to believe, that accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated, and that as a result, Defendants' public statements were materially false and misleading at all relevant times.

Those who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.